A 62-year-old male ex-smoker (40 pack-years) has dyspnea and chronic productive cough. Spirometry: FEV1/FVC 0.58, FEV1 48% predicted (post-bronchodilator). He is on LABA + LAMA (dual bronchodilator). He continues to have 3 exacerbations per year and blood eosinophils consistently >300 cells/μL. According to GOLD 2024 guidelines, the next most appropriate treatment escalation is:
- A Add roflumilast
- B Switch to LABA + ICS
- C Begin oral prednisolone
- D Add inhaled corticosteroid (ICS) to make triple therapy (LABA+LAMA+ICS) ✓
Explanation
GOLD 2024 recommends triple therapy (LABA + LAMA + ICS) for COPD patients who continue to exacerbate despite dual bronchodilator therapy AND have eosinophil count >300 cells/μL. Blood eosinophils serve as a biomarker predicting ICS response in COPD exacerbation prevention. The ETHOS and KRONOS trials confirmed that triple therapy significantly reduced exacerbations compared to dual therapy in this subgroup. Roflumilast (PDE-4 inhibitor) is an add-on for chronic bronchitis phenotype with FEV1 <50%. ICS as monotherapy or switching from LABA+LAMA to LABA+ICS is suboptimal.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.